Tsz‐Kok Yau

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Supportive care needs in Hong Kong Chinese women confronting advanced breast cancer

Angel Hoe-chi Au, Janice Tsang, Tsz‐Kok Yau et al. · Psycho-Oncology · 2012 · 100 citations

Medicine, Oncology, Breast Oncology +12

Screening for family members of patients with nasopharyngeal carcinoma

Wai Tong Ng, Tsz‐Kok Yau, R Yung et al. · International Journal of Cancer · 2004 · 76 citations · Full text

Medicine, Immunology, Oncology +15

RapidArc radiotherapy planning for prostate cancer: Single-arc and double-arc techniques vs. intensity-modulated radiotherapy

Henry Sze, Michael C.H. Lee, Wai‐Man Hung et al. · Medical dosimetry · 2011 · 60 citations

Medicine, Oncology, Radiation Oncology +16

Retrospective analysis on treating nasopharyngeal carcinoma with accelerated fractionation (6 fractions per week) in comparison with conventional fractionation (5 fractions per week): report on 3-year tumor control and normal tissue toxicity

Anne W.M. Lee, Wai-Man Sze, Tsz‐Kok Yau et al. · Radiotherapy and Oncology · 2001 · 54 citations

Medicine, Oncology, Radiation Oncology +16